Investing.com - Krystal Biotech (NASDAQ: KRYS) reported third quarter EPS of $0.91, $0.08 worse than the analyst estimate of $0.99. Revenue for the quarter came in at $83.8M versus the consensus estimate of $82.94M.
Krystal Biotech's stock price closed at $176.39. It is down -2.21% in the last 3 months and up 44.40% in the last 12 months.
Krystal Biotech saw 2 positive EPS revisions and 1 negative EPS revisions in the last 90 days. See Krystal Biotech's stock price’s past reactions to earnings here.
According to InvestingPro, Krystal Biotech's Financial Health score is "great performance".
Check out Krystal Biotech's recent earnings performance, and Krystal Biotech's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar